Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/bioe.70068 http://scihub22266oqcxt.onion/10.1111/bioe.70068 41353657!?!41353657 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41353657&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Bioethics 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41353657|t=2025. Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large |pdf=|usr=}}{{41353657}} gab.com Text Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large JO: Bioethics http://www.kidney.de/pget.php?&tw=1&pmid=41353657 #FOAvip This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long-term side effects, the exacerbation of weight-based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential. Twit Text FOAVip Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large ????Bioethics http://www.kidney.de/pget.php?&tw=1&pmid=41353657 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41353657 #FOAvip English Wikipedia <ref>{{Cite pmid|41353657}}</ref> Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as Ozempic and Mounjaro: Impact on Individuals and Society at Large #MMPMID41353657 Minerva F Bioethics 2025[Dec]; ? (?): ? PMID41353657show ga This paper explores the ethical implications of emerging weight-loss medications such as Semaglutide (Ozempic) and Tirzepatide (Mounjaro), analysing their therapeutic applications for obesity and potential use as enhancement drugs. These medications promise significant benefits, including improved individual health outcomes, reduced healthcare costs and, potentially, reduced environmental harms. However, their widespread adoption raises various concerns, such as unknown long-term side effects, the exacerbation of weight-based discrimination, and the reinforcement of socioeconomic disparities. The paper argues that, with robust regulatory frameworks in place, the potential benefits of these medications are likely to outweigh the risks. Nonetheless, ongoing monitoring of their effect on individuals and society at large remains essential. ?Ethical Issues Related to the Use of GLP-1 Receptor Agonists Such as O(epmc).pdf DeepDyve Pubget Overpricing